# Boehringer Ingelheim opens $800M biopharma plant in Vienna

Boehringer Ingelheim's new large-scale cell culture manufacturing plant in Vienna, Austria, became operational in October 2021. The project cost over $800 million, adds 185,000 liters of production capacity and 500 new jobs, and includes 48 stainless steel bioreactors.

- Type: Expansion
- Announced: 2021-10-14
- Where: Vienna, Austria
- Value: $800.0M
- Jobs: 500
- Starts operating: 7 Oct 2021
- Status: completed
- Capacity: 185,000 liters
- Products: monoclonal antibodies, enzymes, cytokines, recombinant proteins
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Boehringer Ingelheim](https://endata.com/companies/25171.md)

## Sources

- [endpoints.news](https://endpoints.news/six-years-and-nearly-1b-later-boehringer-ingelheims-largest-ever-investment-is-now-operational/), 2021-10-14: "Last week, the site became operational."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.